Treatment Use Study for Advanced Melanoma.

Expanded access No longer available Pfizer

Summary

The purpose of this study is to provide access to CP-675,206 for patients with advanced unresectable melanoma and who have the potential to gain benefit from this treatment and who are not eligible for participation in other CP-675,206 studies.

Timeline

Start: 2008-05
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tremelimumab	Monoclonal antibody	15 mg/kg	Intravenous

Indications

No indication recorded.